Christine Mau - Publications

Complication rate after implant-based breast-reconstruction with support of a synthetic non-resorbable titanized polypropylene mesh (TiLOOP® Bra): Analysis of the 2-year follow up from the prospective multicentre PRO-BRA trial.

Journal: JPRAS open

Published: December 30, 2025

Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.

Journal: Breast cancer research and treatment

Published: January 10, 2025

How enhancers regulate wavelike gene expression patterns.

Journal: eLife

Published: November 16, 2022

Patient-Reported Outcomes and Aesthetic Results after Immediate Breast Reconstruction Using Human Acellular Dermal Matrices: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study.

Journal: Breast care (Basel, Switzerland)

Published: February 18, 2020

Patient reported outcome and cosmetic evaluation following implant-based breast-reconstruction with a titanized polypropylene mesh (TiLOOP® Bra): A prospective clinical study in 269 patients.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: January 24, 2020

Human Acellular Dermal Matrix (Epiflex®) in Immediate Implant-Based Breast Reconstruction after Skin- and Nipple-Sparing Mastectomy and Treatment of Capsular Fibrosis: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study.

Journal: Breast care (Basel, Switzerland)

Published: January 06, 2020

Prophylactic Surgery: For Whom, When and How?

Journal: Breast care (Basel, Switzerland)

Published: February 20, 2018

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.

Journal: International journal of cancer

Published: October 20, 2014

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 17, 2014

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.

Journal: Breast cancer research and treatment

Published: June 27, 2014

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma.

Journal: Breast cancer research and treatment

Published: January 23, 2014

Breast Cancer during Pregnancy: An Interdisciplinary Approach in Our Institution.

Journal: Breast care (Basel, Switzerland)

Published: August 02, 2013